Table of Content

1. Personalized Cancer Vaccines As Next Generation Immunotherapeutic Approach
1.1 Approach To Cancer Vaccine Strategy
1.2 Cancer Vaccines - Current Progress & Challenges


2. Personalized Cancer Vaccine Mechanism Of Action
2.1 Role of Tumor Neoantigens & Human Leukocyte Antigen
2.2 Personalized Cancer Vaccine Working Mechanism
2.3 Genetic Polymorphism In Pharmacogenomics
2.4 Cancer Pharmacogenomics & Somatic Mutations


3. Role of Biomarkers In Personalized Vaccines
3.1 Pharmacogenomic Biomarkers
3.2 Prognostic & Predictive Biomarkers


4. Provenge – 1st Approved Personalized Cancer Vaccine
4.1 Overview & Patent Insight
4.2 Pricing & Dosing Insight


5. Personalized Cancer Vaccines Clinical Insight By Developer, Indication & Phase


6. Current Clinical Development & Future Commercialization Outlook
6.1 Current Market Development Scenario
6.2 Future Market Outlook


7. Personalized Cancer Vaccines Clinical Tends & Developments Insight By Indication
7.1 Melanoma
7.2 Lung Cancer
7.3 Breast Cancer
7.4 Prostate Cancer
7.5 Gastrointestinal Cancers
7.6 Gynecological Cancers
7.7 Brain Tumor
7.8 Hematological Malignancies


8. Personalized Cancer Vaccines Clinical & Market Insight By Region
8.1 US
8.2 EU
8.3 China
8.4 India
8.5 Australia
8.6 South Korea
8.7 Taiwan
8.8 UK


9. Personalized Cancer Vaccines Proprietary Development Platforms
9.1 BioNTech - iNeST
9.2 BioVaxys - DPX & Haptenix Platforms
9.3 CureVac - proprietary mRNA technology
9.4 Evaxion – PIONEER & ObsERV Technologies
9.5 Geneos - GT-EPIC? platform
9.6 Moderna - mRNA Design Studio
9.7 myNEO Therapeutics - ImmunoEngine
9.8 Nouscom - Unnamed Technology
9.9 Nykode Therapeutics – Vaccibody
9.10 Transgene - myvac



10. Personalized Cancer Vaccine Market Dynamics
10.1 Market Drivers & Opportunities
10.2 Market Challenges & Restraints


11. Competitive Landscape
11.1 BioNtech AG
11.2 CureVac AG
11.3 Evaxion Biotech
11.4 Geneos Therapeutics
11.5 Genentech
11.6 Merck
11.7 Moderna Therapeutics
11.8 NeoCura
11.9 Transgene
11.10 TuHURA Biosciences



List of Figures

Figure 1-1: Cancer Vaccine Types
Figure 1-2: Advantages Of Targeting Neoantigens In Cancer Vaccine Development

Figure 2-1: Personalized Cancer Vaccine - Mechanism
Figure 2-2: Demonstrating Genomic Polymorphism In Pharmacogenomics
Figure 2-3: Source of Pharmacological & Pharmacogenetic Variability

Figure 3-1: Biomarkers In Personalized Medicine
Figure 3-2: Roadmap For Developing Predictive Biomarkers

Figure 4-1: Provenge – Approval Year By Region
Figure 4-2: Provenge – Cost Per Unit & Supply (US$), March’2025

Figure 6-1: Global Personalized Cancer Vaccines Market - Future Outlook

Figure 7-1: KEYNOTE-942 Phase 2 Study (NCT03897881) – Initiation & Completion Year
Figure 7-2: BNT111-01 Phase 2 Study (NCT04526899) – Initiation & Completion Year
Figure 7-3: KEYNOTE-D36 Phase 2 Study (NCT05309421) – Initiation & Completion Year
Figure 7-4: MC210102 Phase 1 Study (NCT05269381) – Initiation & Completion Year
Figure 7-5: INTerpath-002 Phase 3 Study (NCT06077760) – Initiation & Completion Year
Figure 7-6: INTerpath-009 Phase 3 Study (NCT06623422) – Initiation & Completion Year
Figure 7-7: KEYNOTE-603 Phase 1 Study (NCT03313778) – Initiation & Completion Year
Figure 7-8: MCC-20915 Phase 2 Study (NCT05325632) – Initiation & Completion Year
Figure 7-9: FK-PC101-01 Phase 2 Study (NCT06636682) – Initiation & Completion Year
Figure 7-10: 19-039 Phase 1 Study (NCT04161755) – Initiation & Completion Year
Figure 7-11: IMCODE003 Phase 2 Study (NCT05968326) – Initiation & Completion Year
Figure 7-12: GT-30 Phase 1/2 Study (NCT04251117) – Initiation & Completion Year
Figure 7-13: QUILT 502 Phase 1/2 Study (NCT06253494) – Initiation & Completion Year

Figure 9-1: BioNTech - iNeST
Figure 9-2: BioVaxys - DPX & Haptenix Platforms
Figure 9-3: CureVac - proprietary mRNA technology
Figure 9-4: Evaxion –Proprietary Technologies
Figure 9-5: Geneos - GT-EPIC Platform
Figure 9-6: Moderna - mRNA Design Studio Features
Figure 9-7: myNEO Therapeutics - ImmunoEngine
Figure 9-8: Nouscom - Unnamed Technology
Figure 9-9: Nykode Therapeutics – Vaccibody Structure
Figure 9-10: Nykode Therapeutics – Vaccibody Mechanism Of Action
Figure 9-11: Transgene - myvac Platform

Figure 10-1: Global Personalized Cancer Vaccines Market - Drivers & Opportunities
Figure 10-2: Global Personalized Cancer Vaccines Market - Challenges & Restraints

List of Tables

Table 5-1: Personalized Cancer Vaccines By Developer, Indication & Phase

Table 7-1: Melanoma - Personalized Vaccines In Clinical Trials
Table 7-2: Lung Cancer - Personalized Vaccines In Clinical Trials
Table 7-3: Breast Cancer - Personalized Vaccines In Clinical Trials
Table 7-4: Prostate Cancer - Personalized Vaccines In Clinical Trials
Table 7-5: Gastrointestinal Cancer - Personalized Vaccines In Clinical Trials
Table 7-6: Gynecological Cancer - Personalized Vaccines In Clinical Trials
Table 7-7: Brain Cancer - Personalized Vaccines In Clinical Trials
Table 7-8: Hematological Malignancies - Personalized Vaccines In Clinical Trials